DnB Asset Management’s MiNK Therapeutics INKT Stock Holding History
Bought
Maintained
Sold
Other funds holding INKT
BS
DnB Asset Management's INKT Position: Q3 2026 in Review
DnB Asset Management reduced its MiNK Therapeutics (INKT) stake by 20% in Q3 2026, selling an estimated $127K and leaving 43,960 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #750.
DnB Asset Management first reported a position in INKT in Q2 2026 and has held it in 2 quarters since. The position peaked at $645K in Q2 2026. 26 funds tracked by Wall St. Rank hold INKT as of Q3 2026.
- DnB Asset Management held 43,960 shares of MiNK Therapeutics worth $552K as of Q3 2026.
- DnB Asset Management sold 11,182 MiNK Therapeutics shares in Q3 2026, an estimated $127K.
- MiNK Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q3 2026, its #750 holding.
- DnB Asset Management first reported a position in MiNK Therapeutics in Q2 2026 and has held it in 2 quarters since.
- DnB Asset Management's MiNK Therapeutics position peaked at $645K in Q2 2026.
- 26 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.
Based on DnB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.